1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

15 Jul 2024
Admin
News Article

Bristol Myers Squibb’s Opdualag Approved by SMC for Advanced Melanoma

Overview

Bristol Myers Squibb (BMS) has announced that its new immunotherapy combination, Opdualag (nivolumab-relatlimab), has been accepted by the Scottish Medicines Consortium (SMC) for use within NHS Scotland for advanced melanoma.

LAG-3 Blocking Antibody Combination

Providing an additional treatment option for eligible patients in Scotland living with the form of skin cancer, the first approved LAG-3 blocking antibody combination is indicated as a first-line treatment in adults and adolescents 12 years of age and older living with the disease.

Melanoma in UK

Currently the fifth-most common cancer in the UK, melanoma is a type of skin cancer that develops when pigment-producing cells located in the skin grow uncontrollably.
The condition affects more than 1,200 people in Scotland every year and approximately 10% of all cases in the UK are diagnosed at more advanced stages, leading to poorer outcomes.

Phase 2/3 RELATIVITY-047 Trial

The SMC’s decision was based on results from the phase 2/3 RELATIVITY-047 trial, which has been evaluating Opdualag compared to nivolumab alone in 714 patients with previously untreated metastatic or unresectable stage 3 or 4 melanoma.
The trial achieved its primary endpoint after the combinative immunotherapy more than doubled median progression-free survival after a median follow-up of 19.3 months, compared to nivolumab monotherapy.

From BMS UK & Ireland

Commenting on the decision, Guy Oliver, general manager, BMS UK and Ireland, said: “We are proud that the [Opdualag] combination… is now a treatment option for eligible adults and adolescents living with advanced melanoma in Scotland.
“Results from the RELATIVITY-047 study demonstrated the clinical impact of this novel combination treatment, representing our ongoing commitment to helping improve patient outcomes in melanoma and bring immunotherapy to more patients.”

For Anti-Tumour Immune Response

Already approved via the Project Orbis programme, coordinated by the US Food and Drug Administration, the Medicines and Healthcare products Regulatory Agency, and other regulatory bodies to review and approve cancer treatments that have been licenced in collaboration with other regulators, Opdualag is designed to harness the body’s own immune system to help restore its anti-tumour immune response.

The SMC’s decision comes after the National Institute for Health and Care Excellence recommended Opdualag in England and Wales in January this year as a first-line treatment of advanced melanoma in patients aged 12 years and older.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!